Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.

RR, Henry; J, Rosenstock; S, Edelman; S, Mudaliar; AG, Chalamandaris; S, Kasichayanula; A, Bogle; N, Iqbal; J, List; SC, Griffen

doi:10.2337/dc13-2955

Public

Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.

Shared by NobleBlocks on Sep 30, 2014 • 12:00 AM UTC

Authors:

Henry RR

Rosenstock J

Edelman S

Abstract

<h4>Objective</h4>Insulin adjustments to maintain glycemic control in individuals with type 1 diabetes often lead to wide glucose fluctuations, hypoglycemia, and increased body weight. Dapagliflozin, an insulin-independent sodium-glucose cotransporter 2 (SGLT2) inhibitor, increases glucosuria and re...

Discussions